IL324630A - Isandrogeroploid analogues and method of treating them - Google Patents

Isandrogeroploid analogues and method of treating them

Info

Publication number
IL324630A
IL324630A IL324630A IL32463025A IL324630A IL 324630 A IL324630 A IL 324630A IL 324630 A IL324630 A IL 324630A IL 32463025 A IL32463025 A IL 32463025A IL 324630 A IL324630 A IL 324630A
Authority
IL
Israel
Prior art keywords
compound
disease
formula
condition
pharmaceutically acceptable
Prior art date
Application number
IL324630A
Other languages
English (en)
Hebrew (he)
Inventor
Subbaraju Venkata Gottumukkala
Kiran Cherukupalli
Bryan Hurst Norman
Prabhakar K Jadhav
Sotirios K Karathanasis
Goutam Mandal
Indranil Mukhopadhyay
Original Assignee
Enveda Therapeutics Inc
Subbaraju Venkata Gottumukkala
Kiran Cherukupalli
Bryan Hurst Norman
Prabhakar K Jadhav
Sotirios K Karathanasis
Goutam Mandal
Indranil Mukhopadhyay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enveda Therapeutics Inc, Subbaraju Venkata Gottumukkala, Kiran Cherukupalli, Bryan Hurst Norman, Prabhakar K Jadhav, Sotirios K Karathanasis, Goutam Mandal, Indranil Mukhopadhyay filed Critical Enveda Therapeutics Inc
Publication of IL324630A publication Critical patent/IL324630A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL324630A 2023-05-18 2024-05-17 Isandrogeroploid analogues and method of treating them IL324630A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363503156P 2023-05-18 2023-05-18
PCT/US2024/030111 WO2024239001A2 (en) 2023-05-18 2024-05-17 Isoandrographolide analogs and method for treatment using the same

Publications (1)

Publication Number Publication Date
IL324630A true IL324630A (en) 2026-01-01

Family

ID=93519990

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324630A IL324630A (en) 2023-05-18 2024-05-17 Isandrogeroploid analogues and method of treating them

Country Status (12)

Country Link
EP (1) EP4712957A2 (de)
JP (1) JP2026521119A (de)
KR (1) KR20260026485A (de)
CN (1) CN121532179A (de)
AU (1) AU2024271399A1 (de)
CL (1) CL2025003577A1 (de)
IL (1) IL324630A (de)
JO (1) JOP20250284A1 (de)
MX (1) MX2025013734A (de)
PE (1) PE20260566A1 (de)
TW (1) TW202509038A (de)
WO (1) WO2024239001A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4376396A (en) * 1994-12-06 1996-06-26 Paracelsian, Inc. Use of andrographolide compounds to treat or prevent pathogenicity of diseases
CN101028260A (zh) * 2007-02-06 2007-09-05 中国药科大学 取代的异穿心莲内酯衍生物的用途
PL2897608T3 (pl) * 2013-04-22 2019-07-31 Innobioscience, Llc Leczenie choroby Alzheimera i zaburzeń poznawczych za pomocą andrografolidów
US10064841B1 (en) * 2018-01-08 2018-09-04 King Saud University Isoandrographolide-19-propionate for treatment of non-alcoholic fatty liver disease (NAFLD)
WO2019166003A1 (zh) * 2018-03-02 2019-09-06 郑州大学 14-脱氧-11,12-脱氢-8,12-环氧或7,8-烯-穿心莲内酯及其15位取代衍生物和用途

Also Published As

Publication number Publication date
KR20260026485A (ko) 2026-02-26
TW202509038A (zh) 2025-03-01
CN121532179A (zh) 2026-02-13
EP4712957A2 (de) 2026-03-25
JOP20250284A1 (ar) 2025-11-16
CL2025003577A1 (es) 2026-04-06
AU2024271399A1 (en) 2025-12-18
JP2026521119A (ja) 2026-06-26
WO2024239001A2 (en) 2024-11-21
PE20260566A1 (es) 2026-03-10
MX2025013734A (es) 2026-03-02
WO2024239001A3 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
US20070191462A1 (en) Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
JP6337109B2 (ja) ナトリウムチャネルの調節剤としてのスルホンアミド
ES2532356T3 (es) N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP6592702B1 (ja) Ｎａｖ１．７およびＮａｖ１．８遮断薬としてのアミド誘導体
JP2013532186A (ja) 化合物
US7960407B2 (en) Crystal forms of an imidazole derivative
JP2009523842A (ja) ナトリウムチャネルモジュレーターとしてのピリジン誘導体
US20090227562A1 (en) Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
HK1251553A1 (zh) 苯并异恶唑衍生物盐
JP2024526952A (ja) 結晶形
JP5898767B2 (ja) エンケファリン類似体
EP4712957A2 (de) Isoandrographolidanaloga und behandlungsverfahren damit
WO2025155874A1 (en) Methods and compounds for modulating immune response
EP1791599A1 (de) Kombination aus einem 5-ht(1) rezeptor-agonisten und einem alpha-2-delta-liganden zur behandlung von migräne
US20250186419A1 (en) Dosing regimens for treating pain
WO2006056874A1 (en) Salt form
JP2009515943A (ja) アミノ酸誘導体
WO2024239000A2 (en) G-protein coupled receptor antagonist
US20080293746A1 (en) Combinations comprising pregabalin
US20090286875A1 (en) Isocystene derivatives for the treatment of pain
WO2009136375A1 (en) Treatment of interstitial cystitis
OA18626A (en) Sulfonamides as modulators of sodium channels.
HK40002696A (en) Amide derivatives as nav1.7 and nav1.8 blockers
HK40002696B (en) Amide derivatives as nav1.7 and nav1.8 blockers
HK1108831A (en) Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor